| Sep 3 |
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 30 |
Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio
|
| Aug 8 |
Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 8 |
Verve Therapeutics GAAP EPS of -$0.59 beats by $0.09, revenue of $6.69M beats by $3.98M
|
| Aug 8 |
Verve Therapeutics: Q2 Earnings Snapshot
|
| Aug 8 |
Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
|
| Aug 1 |
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
|
| Jul 8 |
Why Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now?
|
| Jul 4 |
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
|
| Jun 28 |
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
|
